Neuronal nicotinic receptors (nAChRs) hold very considerable promise as therapeutic targets for treatments of disorders of the CNS and peripheral nervous systems.
Drugs aim ed at nAChRs have potential for the treatment of neurodegenerative disorders, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety and pain, as well as nicotine addiction. Our overall objective is to address the deficiency in drugs selective for nAChR subtypes. To do this, we will carry out studies to synthesize and/or chemically modify molecules belonging to one of several families of products known to have high affinities for nAChRs. Each of the chemical entities that is prepared will be evaluated in a battery of assays to measure its binding affinity at seven different nAChR receptor subtypes stably expressed in mammalian cells and to determine its functional activity as an agonist, competitive antagonist or noncompetitive antagonist. The goals of this research are to provide new pharmacological tools for studies of these receptors and the critical structure activity information that can lead or contribute to the development of nAChR subtype selective drugs to treat human diseases. To meet these objectives, we will pursue the following specific aims: To conduct synthesis and chemical modifications based on molecules already known to possess important properties at nAChR, namely: epibatidine (a high affinity agonist at all nAChR subtypes tested except alpha7), cytosine (an agonist at receptors containing beta4 subunits and a partial agonist at receptors containing beta2subunits), A-85380 (a high affinity agonist at receptors beta subunits), and erysodine (a competitive antagonist with high affinity for receptors containing beta subunits). To characterize each of the ligands prepared in the chemistry effort for their ability to act at nicotinic receptors by assaying its binding affinities at seven nAChR subtypes stably expressed in mammalian cells, and to determine if it has agonist, competitive antagonist or noncompetitive antagonist activity. Functional activity will be evaluated using established 86RbC1 efflux assays and/or whole cell patch clamp measurements.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
1R01DA017980-01A1
Application #
6679753
Study Section
Special Emphasis Panel (ZRG1-MDCN-2 (01))
Program Officer
Hillery, Paul
Project Start
2003-09-30
Project End
2008-06-30
Budget Start
2003-09-30
Budget End
2004-06-30
Support Year
1
Fiscal Year
2003
Total Cost
$284,613
Indirect Cost
Name
University of Illinois at Chicago
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
098987217
City
Chicago
State
IL
Country
United States
Zip Code
60612
Eaton, J Brek; Lucero, Linda M; Stratton, Harrison et al. (2014) The unique ?4+/-?4 agonist binding site in (?4)3(?2)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology versus the (?4)2(?2)3 subtype. J Pharmacol Exp Ther 348:46-58
Kozikowski, Alan P; Eaton, J Brek; Bajjuri, Krishna Mohan et al. (2009) Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression. ChemMedChem 4:1279-91
Cucchiaro, Giovanni; Xiao, Yingxian; Gonzalez-Sulser, Alfredo et al. (2008) Analgesic effects of Sazetidine-A, a new nicotinic cholinergic drug. Anesthesiology 109:512-9
Kozikowski, Alan P; Chellappan, Sheela K; Xiao, Yingxian et al. (2007) Chemical medicine: novel 10-substituted cytisine derivatives with increased selectivity for alpha4beta2 nicotinic acetylcholine receptors. ChemMedChem 2:1157-61
Kozikowski, Alan P; Chellappan, Sheela K; Henderson, David et al. (2007) Acetylenic pyridines for use in PET imaging of nicotinic receptors. ChemMedChem 2:54-7
Xiao, Yingxian; Fan, Hong; Musachio, John L et al. (2006) Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol 70:1454-60
Chellappan, Sheela K; Xiao, Yingxian; Tueckmantel, Werner et al. (2006) Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity. J Med Chem 49:2673-6
Wei, Zhi-Liang; Xiao, Yingxian; Yuan, Hongbin et al. (2005) Novel pyridyl ring C5 substituted analogues of epibatidine and 3-(1-methyl-2(S)-pyrrolidinylmethoxy)pyridine (A-84543) as highly selective agents for neuronal nicotinic acetylcholine receptors containing beta2 subunits. J Med Chem 48:1721-4
Wei, Zhi-Liang; Xiao, Yingxian; Kellar, Kenneth J et al. (2004) Synthesis and pharmacological characterization of bivalent ligands of epibatidine at neuronal nicotinic acetylcholine receptors. Bioorg Med Chem Lett 14:1855-8